Viridian Therapeutics, Inc. (VRDN)
18.22
-0.08
(-0.44%)
USD |
NASDAQ |
Oct 13, 16:00
19.00
+0.78
(+4.28%)
After-Hours: 20:00
Viridian Therapeutics EPS Diluted (TTM) : -3.708 for June 30, 2026
EPS Diluted (TTM) Chart
Historical EPS Diluted (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.708 |
| March 31, 2026 | -3.764 |
| December 31, 2025 | -3.806 |
| September 30, 2025 | -3.534 |
| June 30, 2025 | -4.265 |
| March 31, 2025 | -4.048 |
| December 31, 2024 | -3.774 |
| September 30, 2024 | -4.313 |
| June 30, 2024 | -4.250 |
| March 31, 2024 | -4.505 |
| December 31, 2023 | -5.324 |
| September 30, 2023 | -5.107 |
| June 30, 2023 | -4.872 |
| March 31, 2023 | -4.662 |
| December 31, 2022 | -4.032 |
| September 30, 2022 | -4.212 |
| June 30, 2022 | -4.611 |
| March 31, 2022 | -5.764 |
| December 31, 2021 | -7.694 |
| September 30, 2021 | -29.46 |
| June 30, 2021 | -29.68 |
| March 31, 2021 | -29.28 |
| December 31, 2020 | -29.02 |
| September 30, 2020 | -10.64 |
| June 30, 2020 | -14.58 |
| Date | Value |
|---|---|
| March 31, 2020 | -17.07 |
| December 31, 2019 | -20.06 |
| September 30, 2019 | -20.39 |
| June 30, 2019 | -19.37 |
| March 31, 2019 | -19.42 |
| December 31, 2018 | -16.47 |
| September 30, 2018 | -15.80 |
| June 30, 2018 | -15.45 |
| March 31, 2018 | -16.20 |
| December 31, 2017 | -22.50 |
| September 30, 2017 | -125.84 |
| June 30, 2017 | -1678.79 |
| March 31, 2017 | -1725.44 |
| December 31, 2016 | -1774.94 |
| September 30, 2016 | -1730.29 |
| June 30, 2016 | -261.04 |
| March 31, 2016 | -283.54 |
| December 31, 2015 | -326.29 |
| September 30, 2015 | -397.57 |
| June 30, 2015 | -406.57 |
| March 31, 2015 | -586.57 |
| December 31, 2014 | -496.93 |
| September 30, 2014 | -399.32 |
| June 30, 2014 | -339.89 |
| December 31, 2013 | -189.20 |
EPS Diluted (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (TTM) Benchmarks
| Vertex Pharmaceuticals, Inc. | 17.19 |
| TG Therapeutics, Inc. | 2.746 |
| Travere Therapeutics, Inc. | -0.7636 |
| ACADIA Pharmaceuticals, Inc. | 2.220 |
| Alnylam Pharmaceuticals, Inc. | 5.923 |